The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia
Open accessAbstract
BACKGROUND: The provision of sufficient basal insulin to normalize fasting plasma glucose levels may reduce cardiovascular events, but such a possibility has not been formally tested. METHODS: We randomly assigned 12,537 people (mean age, 63.5 years) with cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes to receive insulin glargine (with a target fasting blood glucose level of ≤95 mg per deciliter [5.3 mmol per liter]) or standard care and to receive n-3 fatty acids or placebo with the use of a 2-by-2 factorial design. The results of the comparison between insulin glargine and standard care are reported here. The coprimary outcomes were nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes and these events plus revascularization or hospitalization for heart failure. Microvascular outcomes, incident diabetes, hypoglycemia, weight, and cancers were also compared between groups. RESULTS: The median follow-up was 6.2 years (interquartile range, 5.8 to 6.7). Rates of incident cardiovascular outcomes were similar in the insulin-glargine and standard-care groups: 2.94 and 2.85 per 100 person-years, respectively, for the first coprimary outcome (hazard ratio, 1.02; 95% confidence interval [CI], 0.94 to 1.11; P=0.63) and 5.52 and 5.28 per 100 person-years, respectively, for the second coprimary outcome (hazard ratio, 1.04; 95% CI, 0.97 to 1.11; P=0.27). New diabetes was diagnosed approximately 3 months after therapy was stopped among 30% versus 35% of 1456 participants without baseline diabetes (odds ratio, 0.80; 95% CI, 0.64 to 1.00; P=0.05). Rates of severe hypoglycemia were 1.00 versus 0.31 per 100 person-years. Median weight increased by 1.6 kg in the insulin-glargine group and fell by 0.5 kg in the standard-care group. There was no significant difference in cancers (hazard ratio, 1.00; 95% CI, 0.88 to 1.13; P=0.97). CONCLUSIONS: When used to target normal fasting plasma glucose levels for more than 6 years, insulin glargine had a neutral effect on cardiovascular outcomes and cancers. Although it reduced new-onset diabetes, insulin glargine also increased hypoglycemia and modestly increased weight. (Funded by Sanofi; ORIGIN ClinicalTrials.gov number, NCT00069784.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both insulin glargine U100 and insulin degludec have demonstrated cardiovascular safety in dedicated CVOTs (207,208).”
From Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022) · cites this paper as [208]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There are a number of other trials regarding cardiovascular outcomes in high-risk cohorts of patients with type 2 diabetes in which similar magnitude effects on glycemic control have been shown but without significant benefits with respect to rates of cardiovascular events or death.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“ORIGIN reported a 1.6 kg gain over 6 years with insulin glargine [46].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [46]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Modest survival benefits also have been reported for breast, ovarian, endometrial, prostate, lung, kidney, liver, and earlier stage pancreatic cancers.1791–1800”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1800]
Experimental — accuracy not yet measuredIn the citing paper
“The following drug classes were excluded due to lack of current evidence of efficacy in cardiovascular outcome trials: dipeptidyl peptidase-4 inhibitors,19 sulfonylureas,20 and insulin.21,22”
From Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis (2025) · cites this paper as [21]
In the citing paper
“It is associated with a lower risk of death and HF hospitalization compared with insulin and sulphonylureas in observational studies, though dedicated randomized, controlled, CVOTs evaluating safety and efficacy of metformin have not been conducted.[555][556][557]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [555]
In the citing paper
“It is associated with a lower risk of death and HF hospitalization compared with insulin and sulphonylureas in observational studies, though dedicated randomized, controlled, CVOTs evaluating safety and efficacy of metformin have not been conducted.[555][556][557]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [555]
In the citing paper
“These trials have more or less uniformly demonstrated a benefit, with lifestyle more efficacious than all medications with the exception of the thiazolidinediones140–152.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [146]
In the citing paper
“In the only RCT of insulin vs. placebo [ORIGIN, 12 537 people with CV risk factors plus impaired fasting glucose, impaired glucose tolerance, or T2DM (i.e.not in patients with HF)], insulin was not associated with higher rates of HF hospitalization than placebo.187”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [187]
In the citing paper
“Lowering glucose without addressing the vascular effects of insulin resistance may be insufficient to reduce risk of cardiovascular events.”
From The Vasculature in Prediabetes (2018) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726
Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults
Selvin, E., Steffes, M. W., Zhu, H., Matsushita, K., Wagenknecht, L., Pankow, J., Coresh, J., & Brancati, F. L. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908359 · Cited by 1,544
Flagged first, then by citations
Research works printed but not linked: 1
- Gerstein H, 2008, Am Heart J, 155, 26
Cited by
Sorted by citations
Items 401–500 of 999
The metabolic vascular syndrome - guide to an individualized treatment
Hanefeld, M., Pistrosch, F., Bornstein, S. R., & Birkenfeld, A. L. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9345-4 · Cited by 44
He, K., Li, W., Chai, X., Yin, Y., Jiang, Y., & Li, W. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3265 · Cited by 41
Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization
Gerstein, H. C., Jung, H. J., Rydén, L., Díaz, R., Gilbert, R. E., & Yusuf, S. (2017) · Circulation · doi:10.1161/circulationaha.117.030924 · Cited by 41
Moreira, R. O., Cobas, R. A., & Coelho, R. C. L. A. (2018) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-018-0327-4 · Cited by 40
An update on pharmacotherapies in diabetic dyslipidemia
Gupta, M., Tummala, R., Ghosh, R. K., Blumenthal, C., Philip, K., Bandyopadhyay, D., Ventura, H. O., & DEEDWANIA, P. C. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.07.006 · Cited by 43
Treatment with Insulin Analog X10 and IGF-1 Increases Growth of Colon Cancer Allografts
Hvid, H., Blouin, M., Birman, E., Damgaard, J., Poulsen, F., Fels, J. J., Fledelius, C., Hansen, B. F., & Pollak, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079710 · Cited by 40
Basal Glucose Can Be Controlled, but the Prandial Problem Persists—It’s the Next Target!
Riddle, M. C. (2017) · Diabetes Care · doi:10.2337/dc16-2380 · Cited by 43
Monami, M., Candido, R., Pintaudi, B., Targher, G., & Mannucci, E. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.05.010 · Cited by 44
Cellular mechanisms and recommended drug-based therapeutic options in diabetic cardiomyopathy
Dannenberg, L., Weske, S., Kelm, M., Levkau, B., & Polzin, A. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107920 · Cited by 40
Adapting Medication for Type 2 Diabetes to a Low Carbohydrate Diet
Cucuzzella, M. T., Riley, K., & Isaacs, D. M. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.688540 · Cited by 42
Wang, P., Huang, R., Lu, S., Xia, W., Sun, H., Sun, J. L., Cai, R., & Wang, S. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0285-1 · Cited by 38
Peralta, F. G., Escalada, J., Torre, E. L. M., Mata‐Cases, M., García, J. C. F., Loiola, P. E., Lachica, L. Á., Pérez, J. A. F., Menéndez, S. A., Guisasola, F. Á., et al. (2018) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2018.08.004 · Cited by 46
Hypoglycemia and Incident Cognitive Dysfunction: A Post Hoc Analysis From the ORIGIN Trial
Cukierman‐Yaffe, T., Bosch, J., Jung, H. J., Punthakee, Z., & Gerstein, H. C. (2018) · Diabetes Care · doi:10.2337/dc18-0690 · Cited by 39
Yasuzawa, T., Nakamura, T., Ueshima, S., & Mima, A. (2021) · Journal of Diabetes Research · doi:10.1155/2021/2182225 · Cited by 39
Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity
Eržen, S., Tonin, G., Jurišić‐Eržen, D., & Klen, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031517 · Cited by 38
U300, a novel long-acting insulin formulation
Sutton, G. L., Minguet, J., Ferrero, C., & Bramlage, P. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.970633 · Cited by 38
The metabolic and mitogenic properties of basal insulin analogues
Tennagels, N., & Ulrich, W. (2013) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2012.754474 · Cited by 38
Reach, G., Pautremat, V. L., & Gupta, S. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s51299 · Cited by 46
Gast, K. B., Smit, J. W. A., den Heijer, M., Middeldorp, S., Rippe, R. C. A., le Cessie, S., de Koning, E. J. P., Jukema, J. W., Rabelink, T. J., Roos, A., et al. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.05.021 · Cited by 38
Insulin Dose and Cardiovascular Mortality in the ACCORD Trial
Siraj, E. S., Rubin, D. J., Riddle, M. C., Miller, M. E., Hsu, F., Ismail‐Beigi, F., Chen, S.-H., Ambrosius, W. T., Thomas, A., Bestermann, W. H., et al. (2015) · Diabetes Care · doi:10.2337/dc15-0598 · Cited by 38
Goldman, J. D., Kapitza, C., Pettus, J., & Heise, T. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1335192 · Cited by 38
Insulin and Its Cardiovascular Effects: What Is the Current Evidence?
Dongerkery, S. P., Schroeder, P. R., & Shomali, M. E. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0955-3 · Cited by 38
Zhang, C., Zhou, Y., Xu, C., Chi, F.-L., & Ju, H.-N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054465 · Cited by 37
The prevention of diabetes and cardiovascular disease in people with schizophrenia
Holt, R. I. G. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12443 · Cited by 37
Roessler, J., Leistner, D. M., Landmesser, U., & Haghikia, A. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.08.018 · Cited by 39
Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit
Ryder, R. E. J. (2014) · Diabetic Medicine · doi:10.1111/dme.12627 · Cited by 37
Insulin Glargine and Cancer Risk in Patients with Diabetes: A Meta-Analysis
Tang, X., Yang, L., He, Z., & Liu, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051814 · Cited by 37
Report of the JDS/JCA Joint Committee on Diabetes and Cancer
Kasuga, M., Ueki, K., Tajima, N., Noda, M., Ohashi, K., Noto, H., Goto, A., Ogawa, W., Sakai, R., Tsugane, S., et al. (2013) · Diabetology International · doi:10.1007/s13340-013-0121-3 · Cited by 37
Consoli, A., Formoso, G., BALDASSARRE, M. P. A., & Febo, F. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1428305 · Cited by 40
Addressing Comorbidities in Heart Failure
Bavishi, A. A., & Patel, R. B. (2020) · Heart Failure Clinics · doi:10.1016/j.hfc.2020.06.005 · Cited by 40
Utzschneider, K. M., Tripputi, M. T., Kozedub, A., Barengolts, E., Caprio, S., Cree‐Green, M., Edelstein, S. L., ghormli, L. K. E., Hannon, T. S., Mather, K. J., et al. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108948 · Cited by 39
Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes
Bonnet, F., & Scheen, A. J. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.04.004 · Cited by 36
The Metabolic Syndrome and Cancer
Pistrosch, F., & Markolf Hanefeld, E. (2013) · Springer eBooks · doi:10.1007/978-3-7091-1331-8_5 · Cited by 36
Optimal management of T2DM remains elusive
Holman, R. R. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.243 · Cited by 37
New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus
Goldman, J. D., & White, J. R. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015597915 · Cited by 36
Clinical Utility of SMBG: Recommendations on the Use and Reporting of SMBG in Clinical Research
Schnell, O., Barnard, K. D., Bergenstal, R. M., Bosi, E., Garg, S. K., Guerci, B., Haak, T., Hirsch, I. B., Ji, L., Joshi, S. R., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2919 · Cited by 36
Hanefeld, M. (2014) · Diabetes & Metabolism · doi:10.1016/j.diabet.2014.08.006 · Cited by 43
Association between beta cell function and future glycemic control in patients with type 2 diabetes
Saisho, Y., Kou, K., Tanaka, K., Abe, T., Shimada, A., Kawai, T., & Itoh, H. (2013) · Endocrine Journal · doi:10.1507/endocrj.ej12-0416 · Cited by 35
Simó, R., Plana‐Ripoll, O., Puente, D., Morros, R., Mundet, X., Vilca, L. M., Hernández, C., Fuentes, I., Procupet, A., Tabernero, J. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079968 · Cited by 34
Bodicoat, D. H., Khunti, K., Srinivasan, B. T., Mostafa, S. A., Gray, L. J., Davies, M. J., & Webb, D. R. (2016) · Diabetic Medicine · doi:10.1111/dme.13091 · Cited by 37
Schernthaner, G., Schernthaner-Reiter, M. H., & Schernthaner, G.-H. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.04.037 · Cited by 38
Du, R., Lin, L., Cheng, D., Xu, Y. H., Xu, M., Chen, Y., Wang, W., Bi, Y., Li, D., & Lu, J. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2961 · Cited by 35
Long-acting insulin analogs and cancer
Sciacca, L., Vella, V., Frittitta, L., Tumminia, A., Manzella, L., Squatrito, S., Belfiore, A., & Vigneri, R. (2018) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2018.02.010 · Cited by 35
ACE and Type 2 Diabetes Risk: A Mendelian Randomization Study
Pigeyre, M., Sjaarda, J., Chong, M., Hess, S., Bosch, J., Yusuf, S., Gerstein, H. C., & Paré, G. (2020) · Diabetes Care · doi:10.2337/dc19-1973 · Cited by 34
Sciacqua, A., Succurro, E., Armentaro, G., Miceli, S., Pastori, D., Rengo, G., & Sesti, G. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10182-x · Cited by 35
The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus
Christensen, M., Miossec, P., Larsen, B. D., Werner, U., & Knop, F. K. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.942638 · Cited by 34
Stoekenbroek, R. M., Rensing, K. L., Moens, S. J. B., Nieuwdorp, M., DeVries, J. H., Zwinderman, A. H., Stroes, E. S. G., Currie, C. J., & Hutten, B. A. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.03.040 · Cited by 36
Habel, L. A., Danforth, K. N., Quesenberry, C. P., Capra, A. M., Eeden, S. K. V. D., Weiss, N. S., & Ferrara, A. M. (2013) · Diabetes Care · doi:10.2337/dc13-0140 · Cited by 34
Arnold, S. V., Echouffo-Tcheugui, J. B., Lam, C. S. P., Inzucchi, S. E., Tang, F., McGuire, D. K., Goyal, A., Maddox, T. M., Sperling, L. S., Fonarow, G. C., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.05.016 · Cited by 35
Sim, R., Chong, C. W., Loganadan, N. K., Fong, A. Y. Y., Navaravong, L., Hussein, Z. B., Khunti, K., & Lee, S. W. H. (2021) · Diabetic Medicine · doi:10.1111/dme.14780 · Cited by 35
Ueng, K., Chiang, C., Chao, T., Wu, Y., Lee, W.-L., Li, Y., Ting, K.-H., Su, C.-H., Lin, H., Su, T., et al. (2023) · PubMed Central · doi:10.6515/acs.202301_39(1).20221103a · Cited by 34
Hanefeld, M., Monnier, L., Schnell, O., & Owens, D. R. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0153-3 · Cited by 36
Impact of Intensive Glycemic Treatment on Diabetes Complications—A Systematic Review
Poonoosamy, J., Lopes, P., Huret, P., Dardari, R., Penfornis, A., Thomas, C., & Dardari, D. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071791 · Cited by 43
Kwon, C. S., Seoane-Vazquez, E. C., & Rodríguez-Monguió, R. (2018) · BMC Health Services Research · doi:10.1186/s12913-018-2860-0 · Cited by 37
Scholtes, R. A., van Baar, M. J. B., Lytvyn, Y., Bjornstad, P., Nieuwdorp, M., Cherney, D. Z. I., & van Raalte, D. H. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13692 · Cited by 34
Shi, S., He, Y., Koya, D., & Kanasaki, K. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12208 · Cited by 33
Heller, S. R., Buse, J. B., Ratner, R. E., Seaquist, E. R., Bardtrum, L., Hansen, C. T., Tutkunkardas, D., & Moses, A. C. (2019) · Diabetes Care · doi:10.2337/dc18-2361 · Cited by 33
Harrington, J. L., de Albuquerque Rocha, N., Patel, K. V., Verma, S., & McGuire, D. K. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1035-z · Cited by 32
Freemantle, N., Danchin, N., Calvi-Gries, F., Vincent, M., & Home, P. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12598 · Cited by 30
Insulin Use Early in the Course of Type 2 Diabetes Mellitus: The ORIGIN Trial
Hanefeld, M., & Bramlage, P. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0366-z · Cited by 33
Safety of antidiabetes medications: An update
Bailey, C. J. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.125 · Cited by 33
Packer, M. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0648-x · Cited by 32
Management of diabetes mellitus in patients undergoing liver transplantation
Grancini, V., Resi, V., Palmieri, E., Pugliese, G., & Orsi, E. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.042 · Cited by 35
Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus
Vijayakumar, S., Vaduganathan, M., & Butler, J. (2018) · Circulation · doi:10.1161/circulationaha.117.032099 · Cited by 32
Wiggers, H., Køber, L., Gislason, G., Schou, M., Poulsen, M. K., Vraa, S., Nielsen, O. W., Bruun, N. E., Nørrelund, H., Hollingdal, M., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.09.020 · Cited by 33
Nanomedicine for the treatment of diabetes-associated cardiovascular diseases and fibrosis
Luo, X., Yan, C., & Feng, Y. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.004 · Cited by 35
Asymptomatic Diabetic Cardiomyopathy: an Underrecognized Entity in Type 2 Diabetes
Stanton, A. M., Vaduganathan, M., Chang, L., Turchin, A., Januzzi, J. L., & Aroda, V. R. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01407-2 · Cited by 33
Nauck, M. A., Mirna, A. E. A., & Quast, D. R. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14988 · Cited by 35
Holden, S. E., Jenkins‐Jones, S., & Currie, C. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153594 · Cited by 31
Lin, J., Lingohr-Smith, M., & Fan, T. (2016) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s117200 · Cited by 31
Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
Lau, I. T., Lee, K. F., So, W. Y., Tan, K. C. B., & Yeung, M. W. (2017) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s131358 · Cited by 31
Mortality in Individuals Treated With Glucose-Lowering Agents: A Large, Controlled Cohort Study
Claesen, M., Gillard, P., Smet, F. D., Callens, M., Moor, B. D., & Mathieu, C. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3184 · Cited by 31
Impact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes
Lau, D. C. W., & Teoh, H. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.09.090 · Cited by 33
Prevalence of prediabetes and associated risk factors in a rural Nigerian community
Nwatu, C. B., Ofoegbu, E., Unachukwu, C., Young, E. E., Okafor, C. I., & Okoli, C. E. (2015) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-015-0401-5 · Cited by 36
Chiang, C., Ueng, K.-C., Chao, T., Lin, T., Wu, Y.-J., Wang, K.-L., Sung, S., Yeh, H., Li, Y., Liu, P., et al. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000359 · Cited by 30
Early Insulinization to Prevent Diabetes Progression
Raz, I., & Mosenzon, O. (2013) · Diabetes Care · doi:10.2337/dcs13-2014 · Cited by 30
Lucidi, P., Porcellati, F., Candeloro, P., Cioli, P., Andreoli, A. M., Marzotti, S., Schmidt, R., Bolli, G. B., & Fanelli, C. G. (2014) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.02.008 · Cited by 30
New Long-Acting Basal Insulins: Does Benefit Outweigh Cost?
Standl, E., & Owen, D. R. (2016) · Diabetes Care · doi:10.2337/dcs15-3011 · Cited by 31
NMDAR antagonists for the treatment of diabetes mellitus—Current status and future directions
Welters, A., Kluppel, C. A., Mrugala, J., Wörmeyer, L., Meißner, T., Mayatepek, E., Heiß, C., Eberhard, D., & Lammert, E. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13017 · Cited by 34
Lipid Profiles, Inflammatory Markers, and Insulin Therapy in Youth with Type 2 Diabetes
Katz, L. E. L., Bacha, F. F., Gidding, S. S., Weinstock, R. S., ghormli, L. K. E., Libman, I. M., Nadeau, K. J., Porter, K., Marcovina, S. M., McKay, S. V., et al. (2018) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2017.12.052 · Cited by 30
Rosselló, X., Ferreira, J. P., McMurray, J. J. V., Aguilar, D. A., Pfeffer, M. A., Pitt, B., Dickstein, K., Girerd, N., Rossignol, P., Zannad, F. M., et al. (2018) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872618803701 · Cited by 30
Cavaiola, T. S., Kiriakov, Y., & Reid, T. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.11.015 · Cited by 31
Endothelium as a Therapeutic Target in Diabetes Mellitus: From Basic Mechanisms to Clinical Practice
Tentolouris, A., Eleftheriadou, I., Tzeravini, E., Tsilingiris, D., Paschou, S. Α., Siasos, G., & Tentolouris, N. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190119154152 · Cited by 31
Gonna, H., & Ray, K. K. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13691 · Cited by 30
Akoumianakis, I., Badi, I., Douglas, G., Chuaiphichai, S., Herdman, L., Akawi, N. A., Margaritis, M., Antonopoulos, A. S., Oikonomou, E. K., Psarros, C. T., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aav8824 · Cited by 31
Review of Associations Between Type 2 Diabetes and Cancer
Bonagiri, P. R., & Shubrook, J. H. (2020) · Clinical Diabetes · doi:10.2337/cd19-0077 · Cited by 32
Use of Antihyperglycemic Drugs and Risk of Cancer in Patients with Diabetes
Søndergaard, C. S., Esquivel, P. N., Dalamaga, Μ., & Magkos, F. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01344-7 · Cited by 33
Self-Monitoring of Blood Glucose
Schnell, O., Hanefeld, M., & Monnier, L. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814528134 · Cited by 31
One size does not fit all glycemic targets for type 2 diabetes
Pozzilli, P., Strollo, R., & Bonora, E. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12206 · Cited by 30
Evidence-Based Management of Diabetes in Older Adults
Mooradian, A. D. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0598-3 · Cited by 31
Tuccinardi, D., Masi, D., Watanabe, M., Zanghi Buffi, V., De Domenico, F., Berti, S., Cipriani, V., Manco, M., Manfrini, S., & Pagotto, U. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02700-7 · Cited by 29
Antidiabetic drugs and risk of cancer
Tokajuk, A., Krzyżanowska-Grycel, E., Tokajuk, A., Grycel, S., Sadowska, A., & Car, H. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2015.05.005 · Cited by 30
Paneni, F. (2013) · Diabetes and Vascular Disease Research · doi:10.1177/1479164113512859 · Cited by 29
Predictive power of cell‐to‐cell variability
Li, B., & You, L. (2013) · Quantitative Biology · doi:10.1007/s40484-013-0013-3 · Cited by 28
Freemantle, N., Mamdani, M., Vilsbøll, T., Kongsø, J. H., Kvist, K., & Bain, S. C. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0142-y · Cited by 29
Near normal HbA1c with stable glucose homeostasis: the ultimate target/aim of diabetes therapy
Monnier, L., Colette, C., Dejager, S., & Owens, D. R. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9325-8 · Cited by 29
Owens, D. R., Monnier, L., & Hanefeld, M. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12998 · Cited by 29
Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus
Sharma, A., Cooper, L. B., Fiuzat, M., Mentz, R. J., Ferreira, J. P., Butler, J., FITCHETT, D. H., Moses, A. C., O’Connor, C. J., & Zannad, F. M. (2018) · JACC Heart Failure · doi:10.1016/j.jchf.2018.05.020 · Cited by 29
Heart Failure Epidemiology in Patients With Diabetes Mellitus Without Coronary Heart Disease
Khan, H., Anker, S. D., Januzzi, J. L., McGuire, D. K., Sattar, N. A., Woerle, H. J., & Butler, J. (2018) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2018.10.015 · Cited by 29
Comparative Effectiveness for Glycemic Control in Older Adults with Diabetes
Quartuccio, M., Buta, B. J., & Kalyani, R. R. (2017) · Current Geriatrics Reports · doi:10.1007/s13670-017-0215-z · Cited by 29
Metadata
- Authors
- The ORIGIN Trial Investigators
- Affiliations
- Population Health Research Institute (CA)
- Corresponding author
- The ORIGIN Trial Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-07-26
- Volume
- 367
- Issue
- 4
- Pages
- 319-328
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1975663485
- Semantic Scholar
- 695c6a8e398d66ae418b143a3491ad91d28443bb
- Cited by
- 1,636
- References
- 29
- Citations by year
- 2026: 34 · 2025: 41 · 2024: 76 · 2023: 86 · 2022: 82 · 2021: 108 · 2020: 101 · 2019: 139 · 2018: 155 · 2017: 152 · 2016: 155 · 2015: 132 · 2014: 168 · 2013: 147 · 2012: 53
- FWCI
- 128.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Monash University Research Portal (Monash University) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- IRIS (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- University of Oxford
- AFA Försäkring
- Hjärt-Lungfonden
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- basal insulin, insulin glargine, impaired fasting glucose, impaired glucose tolerance, type 2 diabetes, cardiovascular outcomes, myocardial infarction, stroke, heart failure, omega-3 fatty acids, hypoglycemia, weight gain, cancer risk, microvascular outcomes, cardiovascular risk factors, revascularization, hospitalization, new-onset diabetes
- MeSH terms
- Insulin Glargine, Aged, Blood Glucose, Cardiovascular Diseases, Cholesterol, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Fasting, Female, Follow-Up Studies, Hospitalization, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Middle Aged, Triglycerides, Fatty Acids, Omega-3, Incidence, Proportional Hazards Models, Glucose Intolerance, Insulin, Long-Acting, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
